Long-term efficacy and safety of iloperidone: An update

Jeffrey T. Rado, Philip G. Janicak

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Schizophrenia is a devastating neuropsychiatric disease with a worldwide prevalence of approximately 0.5%-1%. Since many patients do not achieve adequate symptom relief from available agents, alternate pharmacotherapeutic approaches are needed. In this context, iloperidone was recently approved by the US Food and Drug Administration for the treatment of schizophrenia. This paper first reviews its pharmacodynamic and pharmacokinetic profiles, emphasizing their clinical relevance. Next, it summarizes the literature on its acute and maintenance efficacy, safety, and tolerability. It then considers pharmacogenetic data which may help to predict response and risk of cardiac arrhythmias with this agent. Finally, it critically positions iloperidone relative to other first-and second-generation antipsychotics.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalNeuropsychiatric Disease and Treatment
Volume10
DOIs
StatePublished - Feb 26 2014

Keywords

  • Antipsychotic
  • Iloperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Long-term efficacy and safety of iloperidone: An update'. Together they form a unique fingerprint.

Cite this